576 related articles for article (PubMed ID: 17455349)
1. Microenvironmental pH modulation in solid dosage forms.
Badawy SI; Hussain MA
J Pharm Sci; 2007 May; 96(5):948-59. PubMed ID: 17455349
[TBL] [Abstract][Full Text] [Related]
2. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility.
Tran PH; Tran TT; Lee KH; Kim DJ; Lee BJ
Expert Opin Drug Deliv; 2010 May; 7(5):647-61. PubMed ID: 20205605
[TBL] [Abstract][Full Text] [Related]
3. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility.
Taniguchi C; Kawabata Y; Wada K; Yamada S; Onoue S
Expert Opin Drug Deliv; 2014 Apr; 11(4):505-16. PubMed ID: 24472170
[TBL] [Abstract][Full Text] [Related]
4. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
Kołodziejczyk MK; Kołodziejska J; Zgoda MM
Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
[TBL] [Abstract][Full Text] [Related]
5. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183
[TBL] [Abstract][Full Text] [Related]
6. Practical considerations in development of solid dosage forms that contain cyclodextrin.
Miller LA; Carrier RL; Ahmed I
J Pharm Sci; 2007 Jul; 96(7):1691-707. PubMed ID: 17243148
[TBL] [Abstract][Full Text] [Related]
7. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L
Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270
[TBL] [Abstract][Full Text] [Related]
8. Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
Hou HH; Jia W; Liu L; Cheeti S; Li J; Nauka E; Nagapudi K
Pharm Res; 2018 Jan; 35(2):37. PubMed ID: 29380076
[TBL] [Abstract][Full Text] [Related]
9. Citric acid as a pH-modifying additive in an extended release pellet formulation containing a weakly basic drug.
Ploen J; Andersch J; Heschel M; Leopold CS
Drug Dev Ind Pharm; 2009 Oct; 35(10):1210-8. PubMed ID: 19555250
[TBL] [Abstract][Full Text] [Related]
10. A novel pH-dependent gradient-release delivery system for nitrendipine II. Investigations of the factors affecting the release behaviors of the system.
Yang M; Cui F; You B; Wang L; Yue P; Kawashima Y
Int J Pharm; 2004 Nov; 286(1-2):99-109. PubMed ID: 15501006
[TBL] [Abstract][Full Text] [Related]
11. Sustained release dosage forms dissolution behavior prediction: a study of matrix tablets using NIR spectroscopy.
Tabasi SH; Moolchandani V; Fahmy R; Hoag SW
Int J Pharm; 2009 Dec; 382(1-2):1-6. PubMed ID: 19660535
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical principles of controlled release solid dispersion containing a poorly water-soluble drug.
Tran TT; Tran PH; Lim J; Park JB; Choi SK; Lee BJ
Ther Deliv; 2010 Jul; 1(1):51-62. PubMed ID: 22816119
[TBL] [Abstract][Full Text] [Related]
13. Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone.
Hardy IJ; Windberg-Baarup A; Neri C; Byway PV; Booth SW; Fitzpatrick S
Int J Pharm; 2007 Jun; 337(1-2):246-53. PubMed ID: 17306477
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of the maleate salt of a basic drug by adjustment of microenvironmental pH in solid dosage form.
Zannou EA; Ji Q; Joshi YM; Serajuddin AT
Int J Pharm; 2007 Jun; 337(1-2):210-8. PubMed ID: 17296277
[TBL] [Abstract][Full Text] [Related]
15. Klucel™ EF and ELF polymers for immediate-release oral dosage forms prepared by melt extrusion technology.
Mohammed NN; Majumdar S; Singh A; Deng W; Murthy NS; Pinto E; Tewari D; Durig T; Repka MA
AAPS PharmSciTech; 2012 Dec; 13(4):1158-69. PubMed ID: 22961411
[TBL] [Abstract][Full Text] [Related]
16. Preformulation considerations for controlled release dosage forms. Part II. Selected candidate support.
Chrzanowski F
AAPS PharmSciTech; 2008; 9(2):639-45. PubMed ID: 18431656
[TBL] [Abstract][Full Text] [Related]
17. Indomethacin-Kollidon VA64 Extrudates: A Mechanistic Study of pH-Dependent Controlled Release.
Tres F; Treacher K; Booth J; Hughes LP; Wren SA; Aylott JW; Burley JC
Mol Pharm; 2016 Mar; 13(3):1166-75. PubMed ID: 26845251
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vitro dissolution profile of zidovudine loaded microspheres made of Eudragit RS 100, RL 100 and their combinations.
Nath B; Nath LK; Kumar P
Acta Pol Pharm; 2011; 68(3):409-15. PubMed ID: 21648196
[TBL] [Abstract][Full Text] [Related]
19. Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria.
Taniguchi C; Inoue R; Kawabata Y; Yamashita K; Wada K; Yamauchi Y; Yamada S; Onoue S
Int J Pharm; 2012 Sep; 434(1-2):148-54. PubMed ID: 22643223
[TBL] [Abstract][Full Text] [Related]
20. Salt formation to improve drug solubility.
Serajuddin AT
Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
